Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 2a 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Lethal Congenital Contracture Syndrome 2 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Advanced Solid Tumor Malignancies 1Advanced Solid Tumor 1

Interventions

pembrolizumab 23Carboplatin 6Pemetrexed 5Paclitaxel 4Cisplatin 4130-nm albumin-bound paclitaxel 3spartalizumab 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Axitinib 2Albumin-Bound Paclitaxel 2trametinib 1ribociclib 1osimertinib 1lenvatinib 1etoposide phosphate 1durvalumab 1dabrafenib 1cemiplimab 1binimetinib 1Vascular Endothelial Growth Factor A 1Nivolumab 1Gemcitabine 1Etoposide 1Doxorubicin 1Docetaxel 1DS-8273a 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Antibodies, Bispecific × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡